Luis Valente

📢 Good news! We've extended the application deadline for the 🩺 #Health & #Medical #Technologies #Matchmaking event to September 27. 👥 This online event aims to connect EU-funded #innovators with leading EU-based #corporates, creating opportunities for collaboration at various levels. 👉 Big thanks to CUF - Hospitais e Clínicas and Siemens Healthineers for joining us on 📅 November 6! 🚀 Here are their challenges for innovators: · Automation of clinical tasks and #business support · Ensure patient access to appropriate care in both urgent and scheduled journeys · Promotion of health literacy using new technologies · Improve the quality, speed, and standardization of diagnosis (support for clinical decision-making) · New technologies for patient support throughout their journey (clinical and no clinical) · Solutions to support diagnostics in CT, MR, X-Ray, Molecular Imaging or Ultrasound imaging (also multimodal) · Workflow optimization for medical imaging (e.g. analysis, reporting) · Solutions that support the vision of a Patient Digital Twin and clinical decision making · LLM for #Healthcare/ #MedTech · Robotics for Healthcare (e.g. lab diagnostics, surgery) · Innovative new lab tests for early diagnosis of non-communicable diseases · Innovative offerings for new products or business models for decentralized patient testing (e.g. self-collected blood collection) 👉 Secure your spot now and be part of the future of health tech: https://lnkd.in/d-Curxxj

5

I’m thrilled to be part of the Scaling Up Program by Unicorn Factory Lisboa, where I have the privilege of mentoring highly promising growth-stage startups. Launched in 2023, this is Portugal’s first acceleration program dedicated to scaleups, equipping companies with the strategic guidance and resources needed to scale successfully and positioning Lisbon as a global hub of innovation: * 40 scaleups selected from 148 applicants * 1305 people employed, raising €309M in total capital * Scaleups grew by 29% in employees and 65% in funding during the 8-month program * 84 investment, corporate, and ecosystem partners backing the initiative * +140 C-level mentors from unicorns, scaleups, corporates, and venture capitals If you’re a scaleup with a strong team, generating revenue, and scaling fast, this program is for you - apply here by Sep 29: https://lnkd.in/dia5gK8F Really excited to get to know and support even more startups in scaling and succeeding!   #StartupMentoring #Scaleup #Innovation #UnicornFactoryLisboa #ScalingUpProgram #Entrepreneurship #GrowthStage #LisbonInnovation #ScalingStartups

84

1 Comment

📢 Boston calling - Oportunidades para startups  📍 Startups from Europe and North America ⏳ Until 15 December They are selecting 40 startups to pitch at HTVD | HIGHTECH VENTURE DAYS in #Boston. The selected startups will be prepared individually for their participation, including a review of their pitch and the preselection of relevant investors to talk to at the event. 📅 7/8 April in #Boston ⏺ High profile meeting for Startups, VCs and Corporates ⏺ Exclusivity: selected Startups and investors only  ⏺  Focus Areas: Cleantech | Electronics | Manufacturing | Materials | Mobility | Space & Defense  ⏺ Industrial high-tech: IP-based technologies, B2B, hardware ⏺ Series A+ +Cultura +Criatividade +Sustentabilidade . . . #empreendedorismo #startup #startuplife #startups #empreendedorismodigital #startupbusiness #empreendedorismojovem #businessstartup #startupcompany

3

1 Comment

Really excited to announce our investment in Xgenera! Xgenera are revolutionising cancer diagnosis with their multi-cancer early detection (MCED) test, miONCO, which can identify 12 of the most prevalent and life-threatening cancers at early stages, often before symptoms manifest. Our decision to invest was significantly influenced by Xgenera's exceptional leadership team. Co-founders Dr Andy Shapanis and Professor Paul Skipp bring over 25 years of internationally recognised research experience in oncology and cancer biology. Their dedication to advancing early cancer detection aligns perfectly with our mission to support deep-tech ventures addressing global challenges. We are excited to support Xgenera in their journey to transform cancer diagnostics and improve patient outcomes worldwide. Empirical Ventures, Ascension, QantX Madeleine Nichols, PhD, Johnathan Matlock, Curran Kalha, Ph.D., Trang K. Nguyen, Alexander Fink, Keith Lipman

48

2 Comments

🚀 Innovating Healthcare in Centro Portugal    In collaboration with ULS Coimbra, four innovative SMEs, selected through the HealthChain calls, are co-creating solutions to tackle key healthcare challenges:    🏥 RecoMed – Reducing medication errors in post-op care.  • Solution: MediRecon – A digital platform to ensure safer medication transitions for patients.  • Co-creating the solution: VirtualCare | Technology for a healthier tomorrow & Complear    🧠 Reabilitar@mente – Enhancing cognitive and physical rehabilitation for elderly patients.  • Solution: CogniViTra 2.0 – A personalized platform combining cognitive and motor rehabilitation for improved recovery.  • Co-creating the solution: NeuroInova & Everythink   These collaborations showcase the impact of cross-regional co-creation in enhancing healthcare delivery and patient outcomes.    👉 Learn more here: https://lnkd.in/dp-PFk_A     #HealthcareInnovation #DigitalHealth #SMEs #I3Instrument

46

**Introducing Q2Scale: A Game-Changer for Startups!** EIT Global Outreach has teamed up with Q Europe to launch the Q2Scale programme, an initiative that promises to be a game-changer for startup growth! This partnership offers participants the chance to: 🔹 Conduct pilots 🔹 Collaborate with key European players as design partners 🔹 Accelerate global growth Q2Scale provides top-notch technologies in a comprehensive package for global market penetration and beta testing, all within a 2-month hybrid programme. Focusing on real-world validation, it connects participants with global experts and key players for a successful PoC process. Key Details: - **For startups in**: Automotive, Energy, Supply Chain, or Sustainability sectors. - **For startups with**: A product ready for beta testing. - **For startups aiming to**: Expand to global markets in Europe, Asia, or North America. - **Eligibility**: EU startups or those registered in Horizon Europe-associated countries. Q2Scale is co-led by Q-Europe, a leading ecosystem player facilitating collaborations between startups and industry leaders. Their lead partner, Grand Automotive, operates extensively in mobility services across 13 countries in Central and Southeast Europe. 🗓 **Applications Deadline**: 21 August 2024 🔗 [Apply Now] (https://go-eit.eu/q2scale/) Join us in driving innovation in the startup ecosystem! #EITGlobalOutreach #Q2Scale #Innovation #StartupGrowth #GlobalExpansion

17

3 Comments

Yesterday I argued the only thing that matters for a startup is getting to product-market fit (PMF), quoting Marc Andreessen’s classic blog from 2007. This is part 2 of a mini series on PMF. Here Michael Siebel of Y Combinator explains his thinking on the real PMF. In this video, he explains: - It is often intellectually convenient to claim PMF without having to actually achieve it - founders often forget the real challenge is to solve a problem - PMF is misunderstood 98% of the time, like it’s undefined or a flexibly defined term - it’s often mistaken for something close but different; I built the thing that customers want - PMF is what happens after you have built the things that customers want - the only way you know you’ve built something that customers want is because they’re buying it in an explosive and destructive way - if you’re not getting explosive usage you do not have what customers want or there aren’t that many customers in which case you don’t have a big business - once you find PMF it’s almost like this is going to work unless you screw it up https://lnkd.in/efh6Fpt4

35

6 Comments

Digital Health Acquisitions # 99 - # 105: Week, July, 7th - 13th: Last week we crossed the mark of 100 acquisitions in Digital Health in 2024 with 3 acquisitions in Europe and 4 acquisitions in the US. --- 99: 8 July, SKEZI,a specialist in health data collection, acquired Biosignis, an expert in biological sample valorization. This acquisition aims to enhance SKEZI's offerings and aligns with their strategy to valorize biological data. The move is expected to strengthen SKEZI's position in health research and data utilization 100: 8 July, iktos a company specializing in AI and robotics for new drug design, announced the acquisition of Synsight, a French biotech company focused on AI and high-content cell imaging for drug discovery 101: 9 July, Uwill, a leading online mental health and wellness provider for colleges and students, announced its acquisition of The Virtual Care Group, a Los Angeles-based telehealth company specializing in student wellness support. 102: 9 July, Ospi, a French company specializing in the development of digital health solutions, announced its acquisition of ALICANTE, a software publisher focused on medical imaging and radiology. This strategic move aims to strengthen Ospi's position in the medical imaging software market. 103: 10 July, SAIGroup an enterprise AI investment firm, announced the acquisition of Get Well, a leader in digital patient engagement. Get Well facilitates over 10 million patient interactions annually across more than 1,000 healthcare organizations, joins SAIGroup's portfolio, including ConcertAI and RhythmX AI. 104: 10 July, Accuhealth and Signallamp Health, announced their merger, funded by an additional investment from Sunstone Partners. This strategic move creates a comprehensive suite of remote care services, including RPM and CCM, serving over 300 organizations across 48 U.S. states. 105: 10 July, EnsoData, acquired diagnostic technology from Resonea to expand its capabilities in sleep apnea screening and diagnosis. This acquisition introduces acoustic flow and microphone data channels, which will be integrated into an FDA-cleared mobile application. The new technology allows for pre-screening of patients for sleep apnea using smartphones and enhances home sleep testing diagnostic capabilities. --- As we crossed the 100 acquisitions here is a short summary of the background of such ventures: 1) Cumulatively, the companies raised more than $3.5 billion across 219 deals 2) $1.3 billion of their funding was raised in 2021 - subsequently, these companies only raised <$400 million in the following years until their acquisition 3) 51/105 ventures were incorporated in the past 10 years. 28/51 were incorporated within the past 5 years 4) 58% of the acquired ventures are disease specific with 13/105 focussing on Mental Health

30

1 Comment

📢 Meet the speakers of the 4th Digital Health Conference, 7-8 November in Lisbon 💊 #𝗗𝗛𝗨𝗕𝗜𝗤 Dr. Ricardo Sáinz Fuertes - Global Director of Digital Health Solutions, Eisai EMEA will speak about the NEURii Project - Revolutionising Healthcare for Dementia Patients With Innovative Digital Tools and Cross-Ecosystem Collaboration. In the realm of healthcare, addressing the multifaceted needs of dementia patients requires innovative approaches that integrate technology, compassionate care, and strategic partnerships. NEURii stands at the forefront of this endeavour, poised to transform the landscape of dementia care through a synergistic fusion of Eisai’s Human Health Care (ℎℎ𝑐) concept, the philanthropic vision of Gates Ventures, the ambition to transform the way diseases are identified and treated of LifeArc, the vision to enhance health and care interactions by using large scale data and advanced analytics of Health Data Research UK (HDRUK), and The University of Edinburgh’s pioneering capabilities across health data, AI and neurodegeneration. Eisai's ℎℎ𝑐 concept redefines healthcare delivery by placing the individual at the centre, emphasizing personalized care, proactive interventions, and seamless integration of digital therapeutics. This holistic approach resonates profoundly in dementia care, where individualized support, cognitive stimulation, and caregiver engagement are paramount. ➡ Register here https://lnkd.in/dnGCCigv 📍 Altis Grand Hotel, Lisbon 📆 7&8 November 2024 💺 Limited 100 seats for perfect networking You will also learn from speakers: 🎤Ghaith Sankari, Head of Global Digital Health Data Science, Bayer 🎤Paula Salme Sandrak, Product Strategist (dHealth & Health AI), Bayer 🎤 Dr. Jochen Hurlebaus, Head Digital Health Innovation, Roche Information Solutions 🎤Dr Ricardo Sáinz Fuertes, Global Director Digital Health Solutions NEURii Program Director, Eisai EMEA 🎤Sridevi Nagarajan, Head Digital Regulatory Strategy, AstraZeneca 🎤Lu Zheng, Head of Value-Based Partnerships and Digital Health, Europe & Canada, Takeda 🎤Leslie Anne Fendt, Integrated Solutions Program Lead, Remote Vision Monitoring (myVisionTrack / mVT(x) / Home Vision Monitor), Roche  🎤 Dan Ma, Head of Innovation & New Commercial Partnerships | Head Sandoz Innovation Lab Germany, Sandoz 🎤Ayaka Yanagisawa, Former Head of Data Analytics, Digital Health Solutions, Biogen 🎤Gemma Malla Salomó, Head of Digital Medicines Iberia & Business Unit Head Ophthalmology, Angelini Pharma 🎤Pete Brockmeier, Global Associate Director, Digital Health, Novo Nordisk 🎤Miguel Amador, Partner and Chief Innovation Officer, Complear and others... #DigitalHealth  #HealthcareInnovation #𝗗𝗛𝗨𝗕𝗜𝗤

52

2 Comments

🕵‍♀️ We meet a lot of the founders we invest in at our events. When is the next one, you ask? 13 November, in sunny Lisbon. As someone spending a lot of time between London and Hamburg, I'd say don't go for the money and don't go for the network. Go for the weather. 😉 Jokes aside, even if you don't want to or can't travel, you should still apply, as we review every application - and who knows what will happen... 💫 #diversefounders #impactinvesting #climatetech #inclusiontech

51

8 Comments

In vitro diagnostics for early cancer detection has often been a graveyard for investors. Investors are attracted by the undoubtedly huge market potential. If a company can develop a diagnostic test that is implemented as a population level screening tool, this is the definition of a venture scale opportunity. However, multiple factors are at play that make the journey far from easy. You need a highly sensitive and specific test that allows you to minimise false positives and false negatives. This is because the burden of over diagnosis and over treatment against a change in overall mortality rates is a finely tuned balancing act. You'd also want to ensure that the screening tool was applicable to multi-cancer detection, going further than just a rule-out test, by predicting the origin site of a particular cancer. As a pre-seed/seed investor what we are often looking for is deep scientific domain expertise, coupled with credibility to achieve a proof-of-concept data point and/or prototypes. Our latest investment at Empirical Ventures into Xgenera and the dynamic duo Dr Andy Shapanis and Prof Paul Skipp might just be the right starting point for approaching this opportunity. Their multi cancer early detection test (MCED) called miONCO was developed from analysing relative expression profiles of microRNAs in 20,000 patient samples. Xgenera’s two step test would detect cancer using a computational algorithm to identify microRNA profiles extracted from patient blood samples, and can predict the site of origin of the cancer. As a screening test this could improve patient lives significantly. I believe Xgenera has the right technology, at the right time, based around recent advances in computational speed and power, post-COVID knowledge moats related to qPCR scale-up and novel biomarkers such as microRNAs to capitalise on this potential. Read more about it below. I can't wait to join the board to support the team as they navigate the 0 to 1 phase of this journey. CAPITAL AT RISK. FOR PROFESSIONAL INVESTORS ONLY. https://lnkd.in/dNpuSERg

42

1 Comment

AI is transforming transportation. Meight is the latest example of an AI-powered startup targeting the trucking sector. They are automating workflow for small European carriers. And they just raised $4M led by Cusp Capital. Europe is slow to adopt new transportation tech, but could this be a stepping stone for something bigger? https://lnkd.in/eiQsheT3

34

1 Comment

So, the most stringent AI regulation in history arrived in Europe. What could (and should) you do about it? Without a doubt, the EU AI Act is a significant moment for the European tech sector and especially so for the biotech and healthcare industry. Startups and larger companies will soon have to take care about increased compliance challenges and operational changes, and obviously, additional overhead costs. In a nutshell, the AI act can make life more complicated in the following ways: ✔️ Strict Rules for High-Risk AI: AI used in healthcare, such as diagnostic tools, must pass safety checks, be registered, and carry a European Conformity marking showing compliance. ✔️ Clear User Information: Companies must notify users when AI is involved in their business, such as in patient support or decision-making systems. ✔️ Detailed Documentation: If using versatile AI models (general-purpose AI), startups must keep records on how the AI was built, tested, and its energy use. ✔️ Increased Regulatory Oversight: New bodies like the AI Office will oversee compliance, adding layers to regulatory processes but making them more uniform across Europe. ✔️ Outside EU Impact: The rules apply to companies outside the EU if their AI is used in Europe, potentially increasing costs and affecting product strategies. So, what do we have to know and do about it? This will be the focus of a panel discussion at this year’s SCOPE Europe by Cambridge Healthtech Institute on October 30. Senior associate at LongeVC, Artemy Shumskiy will explore the topic in depth with Ricardo Gaminha Pacheco from Insilico Medicine, Firas ABDESSALEM from Sanofi Christopher Escobedo Hart from Foley Hoag LLP, Gandolf Finke, PhD from Mika and Barnaby Pickering as a moderator. If you’re in Barcelona and attending SCOPE Europe at the end of October, and would like to meet our team, send us an email at hq@longevc.com or DM Artemy Shumskiy. I link the event information to register in the comments. #Europe #artificialintelligence #regulation

47

3 Comments

The interview with Uirá Souto Melo provided by our accelerator partner Start2 Group offers a revealing insight into the ground-breaking work of Lucid Genomics.   After the successful participation in MAX!mize of Max-Planck-Innovation GmbH, the outstanding team of Lucid Genomics - a spin-out from the Max-Planck-Institut für Molekulare Genetik - is now part of the first MPF Start-up Accelerator batch. 💡   Lucid Genomics is doing some truly cutting-edge work in the field of genomics - have you heard of them? Their approach to genomic research is not only innovative but has the potential to make a huge impact on healthcare and technology.   If you’re a start-up looking for opportunities to grow and connect with industry leaders, consider joining the next cohort of the MPF Start-up Accelerator! 🚀 The program is designed to empower ambitious companies like Lucid Genomics to scale and succeed.   The accelerator is hosted by the MPF Start-up Accelerator GmbH which is a wholly owned subsidiary of the Max Planck Foundation.   👉 Sign up today and take your business to the next level! https://lnkd.in/gMJKT8yT   Excited to see what’s next for Lucid Genomics! 🌟 #Genomics #AcceleratorProgram #Biotech #FutureOfHealth

11

1 Comment

Attention of partners, managers, investment directors and private investors investing in Healthtech. Usually they ask you for money and participation in demo day. From me personally and the 4PM Ventures team for you another offer: 1. Please read our post below and express your opinion - do you agree with these theses or not. 2. Ask clarifying questions if they appear. 3. Add to friends if we do not know each other yet. 4. Send our offer to take part in the laboratory to your portfolio companies - the start of the program - a new format for supporting startups, supported by EIT Health, on June 12th. 5. Request an invitation to open a laboratory and a foresight about the future of healthcare, which will take place within the laboratory. More information about the laboratory on the 4PM Ventures page, link to registration in the first comment Dear colleagues, please note this offer: Nathan Kharchenko, Valentin Doronichev; Anna Gishko; Allan Gobbs; Yuri Mashintsev; Jacopo Mele; Marija Varadinova; Yury Kukushkin; Khaled Arwani; Kirill Vesselov; Nikolai Denisov Commercialization Reactor; Zaz Ventures Change Ventures LongeVC; Coöperatie VGZ #4pm; #vc; #health; #healthtech; #medicine

11

2 Comments

Backed by a16z and QED, Brazilian startup Carecode puts AI agents to work on healthcare (HIHUB.TECH🌎Health Innovation♾️Leaders🧬NEWS) Brazilian startup Carecode is among these AI believers. It’s coming out of stealth with an ambition to reduce healthcare costs and improve medical outcomes by developing AI agents that focus on tasks that happen before and after a medical appointment — and would typically be run by a call center. “We tend to think that only the moment with the doctor is what matters, but after having spent 10 years in healthcare I realized that those moments [around the appointment] are as important as the medical encounter,” CEO Thomaz Srougi (pictured right in the above image) told TechCrunch. Srougi comes from a family of doctors, but he’s not one himself; his firsthand knowledge of healthcare comes from founding dr.consulta, a private medical service provider scaleup that’s raised some $168 million in funding, and where he remains chairman. Carecode is still early in its fundraising journey, but already has an impressive cap table: Its $4.3 million pre-seed round was mostly funded by a16z and QED, with participation from Endeavor Catalyst, KDX Ventures , K50 Ventures, and Latitud Ventures, as well as high-profile figures from Brazil’s tech scene, including Nubank founder David Vélez. Venture capital in Latin America is still going through a “startup winter,” but — as this pre-seed raise underscores — there is still funding for entrepreneurs with track records like Srougi and his co-founder, Pedro Magalhães, a former CTO at several other startups, including BEES Bank Brasil and Zé Delivery. Be a Member✨HIHUB.TECH🌎Health Innovation♾️Leaders🧬 https://hihub.in/HIHUBTECH From: Anna Heim, TechCrunch,30/12/24 https://lnkd.in/dtsKzA6f

2

2 Comments